Zai Lab
Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets.
Overview
Founded by Samantha Du; built on Greater China rights to niraparib (Zejula), zanidatamab, repotrectinib, tislelizumab-adjacent assets, sulbactam-durlobactam and Optune, with a Shanghai commercial organisation of hundreds. Internal pipeline: ZL-1310 (DLL3 ADC), ZL-1503 and the LRRC15 ADC ZL-6201 from MediLink. A bridge company: it explains how Western drugs reach Chinese patients years earlier than they otherwise would.
Scorecard
All companies- approved products +24
- targets +8
- modalities +6
- regions +6
- 24-month regulatory events +8
- registry trials +30
Niraparib is a PARP inhibitor approved as maintenance for ovarian cancer regardless of BRCA status, and in prostate cancer with abiraterone.
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.
A ROS1 and NTRK pill that also works after other ROS1 drugs fail, with dizziness as its signature side effect.
Optune is a wearable device delivering electric fields that disrupt cell division. It is approved for glioblastoma and, in 2026, pancreatic cancer.
Pages like this
not linked directly; found by shared links- CompanyHutchmed
Shares Samantha Du (Du Ying) and the tag china.
- CompanyHansoh Pharmaceutical Group
Shares GSK and the tag china.
- TrialPANOVA-3
Shares Novocure, Optune / Optune Pax (TTFields).
- TrialEF-14
Shares Novocure, Optune / Optune Pax (TTFields).
- InstitutionRobert H. Lurie Comprehensive Cancer Center of Northwestern University
Shares Novocure, Optune / Optune Pax (TTFields).
- TechnologyTumour treating fields (TTFields)
Shares Novocure, Optune / Optune Pax (TTFields).
- InstitutionUniversity Hospital Zurich / Comprehensive Cancer Center Zurich
Shares Novocure, Optune / Optune Pax (TTFields).
- CancerGallbladder cancer
Shares Jazz Pharmaceuticals, Zanidatamab.